当前位置: 首页 >> 检索结果
661. [Bladder wall permeability to to topically administered cisplatin].
The aim of the study was quantitation of cisplatinum in the wall of normal urinary bladder, tumor tissue, inflamed mucosa and blood in intravesical administration of cisplatinum. The samples of the tissue were radiated in the flow of heat neutrons 5 x 10(12)-5 x 10(13) neut/cm followed by radiochemical purification of the material and platinum assay in the tissue using analyser LP-4900 with semiconductor radiation detector. The samples were taken from 32 patients with transitional cancer of the bladder. Tumor tissue contained platinum in amounts 33.7 times exceeding those in normal tissue after intravesical administration of 100 mg of the drug. After intravenous administration of 100 mg cisplatinum normal bladder tissue and tumor tissue contained almost similar quantities of the drug. Thus, tumor tissue absorbs more cisplatinum than normal tissue of the bladder in intravesical administration.
662. [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia].
The effect of hypoxy on chemotherapy with emoxyl, 5-fluorouracil and bleomycin which are characterized by different affinities with oxygen has been investigated. In an experiment using 96 rats, each weighing 180 g, subcutaneously inoculated with Walker's carcinosarcoma and carcinoma. PC-1, combined use of chemotherapy and hypoxy was followed by a significant inhibition of tumor growth rate, against a background of significant drop in survival due to the increased toxic effect of the drugs. Therefore, hypoxy cannot be recommended for modifying chemotherapy of tumors irrespective of drug affinity with oxygen.
663. [Combined therapy of experimental tumors with the vaccinal strain of Venezulean encephalomyelitis virus].
The potential of therapy with vaccinal strain of Venezuelan encephalomyelitis virus (VEL) in conjunction with cytostatics (cyclophosphamide) or immunomodulators (T-activin) has been studied. It was found that VEL in conjunction with cyclophosphamide inhibited the antitumor action of the drugs while T-activin potentiated the same effects of the virus and its oncolysate.
664. [The effect of low-energy laser radiation and interferon to delay chemical carcinogenesis].
A significant delay in benz(A)pyrene-induced tumorigenesis was obtained following three series of parenteral injection of xenogenic leukocytic interferon alternating with irradiation at 3-4 day intervals. Radiation was delivered from a red low-energy laser through a puncture in the peritoneal wall of the spleen. When each of said procedures was performed separately similar effects were recorded but the changes were not significant.
665. [Heterogenous reaction of cancer cells to cisplatin].
During a study involving treatment of MCF-7 culture of mammary tumor cells with cisplatin 5.10, 15.20 and 25 microM, an inverse correlation was found between the first two doses and the number of dead cells; later on, this fraction diminished gradually to basal level. Conversely, the fraction of necrotized cells increased in proportion to dosage, overall toxicity of cisplatin (the sum total of dead cells) remaining unchanged when in excess of 10 microM.
666. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].667. [The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].668. [Biotherapy of cancer and protease inhibitors].669. [Bacterial L-asparaginase and glutamin(asparagin)ase: some properties, structure and anti-tumor activity].
Experimental material on structurally and functional organization, regulation of biosynthesis and activity, mechanism of action, genetic determinants, heterologous expression of bacterial L-asparaginases is accumulated. The modern approaches to isolation and purification of these enzymes, some questions of practical using in oncology in the schedules combined chemotherapy of leukemia the native and modified forms of L-asparaginases are discussed. The some results before carried out in the IBMC RAMS and number institutes of the Russia on study bacterial L-asparaginases and glutamine(asparagine)ases are summarized.
670. [Tamoxifen in prophylaxis of breast cancer].671. [Acridonacetic acid: pharmacological properties and clinical use].
The summarized data on the biological activity of acridoneacetic acid, a low-molecular interferon inducer are presented: the amount and type of induced interferon, producer cells, interaction with viruses; the antiviral, antitumoral and anti-inflammatory activity of the preparation has been demonstrated. The specific features of interferon induction by virus (a biological inducer), in contrast to acridoneacetic acid (a chemical inducer) have been noted. The possible mechanisms of interferon induction by low-molecular interferonogen are considered. A number of interferonogens, salts of acridoneacetic acid, proposed as medicinal preparations are considered. The results of the clinical use of Cycloferon, a medicinal form of acridoneacetic acid, are presented.
672. [Recombinant human erythropoietin--blood transfusion alternative].673. [Cytotoxic and cytostatic effect of avermectines on tumor cells in vitro].
作者: V A Mosin.;E B Krugliak.;T S Sterlina.;Iu N Korystov.;V V Shaposhnikova.;A A Narimanov.;L N Kublik.;M Kh Levitman.;A V Viktorov.;V A Driniaev.
来源: Antibiot Khimioter. 2000年45卷10期10-4页
Effect of natural avermectin complex (aversectin C) and separate avermectins A1, A2, B1 and B2 in the cell culture of murine myeloma Ns/o, Erlich carcinoma ascites and human larynx carcinoma Hep-2 was investigated. It was shown that aversectin C within the concentrations of 0.1 to 1.0 mcg/ml inhibited proliferation of tumor cells and induced their death. Proliferation inhibition was due to the delay of the cells cycle start (lag-phase prolongation) and blocking of mitotic cycle. Ns/o cells death had apoptosis signs: chromatin condensation and fragmentation, DNA fragmentation. It was demonstrated that only avermectin A1 has cytotoxic activity within the concentrations used, avermectins A2 and B2 had cytostatic activity, avermectin B1 showed no activity under the experimental conditions.
674. [Clarithromycin and tumor chemotherapy].675. [Morphological estimation of apoptosis in preclinical studies of new drugs].
A method for morphological estimation of the thymus cell loss during apoptosis proposed, which can be used as a screening test in the stage of preclinical characterization of new biologically active compounds. Efficacy of the proposed method is demonstrated by evaluating the degree of apoptosis-inducing effect of some antitumor preparations.
676. [Hemostimulant effect of pantohematogen in myelosuppression induced by cytostatics].
作者: A M Dygaĭ.;L A Gur'iantseva.;V V Zhdanov.;N S Pozhen'ko.;E V Simanina.;N I Suslov.;V E Gol'dberg.
来源: Eksp Klin Farmakol. 2000年63卷6期34-6页
Pantohematogen stimulates hemopoiesis in mice with cyclophosphane induced bone marrow hypoplasia. The hemopoiesis recovery activated by pantohematogen is manifested by the granulocyte lineage hyperplasia in the bone marrow, rapid restoration of the polymorphonuclear leukocyte and monocyte counts in the peripheral blood, and the development of neutrophilia and monocytosis. The activation effect of pantohematogen on the bone marrow hemopoiesis is related to stimulating the precursor cell proliferation and differentiation and to increasing the functional activity of the hemopoietic microenvironment.
677. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Combination chemotherapy with hexamethylmelamine (hexalen, altretamine, hexastat), 100 mg, thrice a day, per os, 14 days (out of a 28-day course) and sarcolysin, 15 mg, per os, during the first 5 days of the course, was received by 24 patients with primary advanced tumors of the ovaries, prior to or after cytoreductive surgery. Total apparent response to chemotherapy among 19 patients of the study group was 47.2%, clinically significant (plus stabilization)--94.5%, without significant untoward side-effects (vomiting--19%; leukopenia degree II-III--33% and thrombocytopenia--19%). The drug proved an active component of combination therapy for advanced ovarian carcinoma.
678. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Miltex (miltefosine) is a new antiproliferation drug comprising phospholipid ingredients. It is used for topical treatment of metastatic skin lesions in breast cancer. Clinical trials of the drug were conducted in 11 breast cancer patients resistant to standard therapy. Apparent therapeutic effect (partial regression) was registered in 27.3% (3/11). Moderate toxic effects were generally confined to skin itching (36.4%) and scaling (18.2%), erythema (18.2%), and paper skin (45.5%).
679. [Cyclophosphamide-induced apoptosis of murine lymphosarcoma cells in vivo].
作者: V I Kaledin.;V P Nikolin.;T A Ageeva.;O A Timofeeva.;M L Filipenko.;G M Ronichevskaia.;T S Morozkova.;N A Popova.;T Iu Baĭmak.
来源: Vopr Onkol. 2000年46卷5期588-93页
The antitumor action of combination chemotherapy (cyclophosphamide + adriamycin + vincristin + prednisolone) for transplantable nitrosomethylurea-induced lymphosarcoma was studied in male CBA mice. Single injections of the mixture were followed by complete regression of tumors of up to 2 cm in diameter. The effect was shown to be caused by cyclophosphamide (CP) alone, by inducing apoptosis. The other components failed to potentiate the CD effect. Being useless, they are likely to cause harm by contributing to the overall toxic effect of therapy. The nature and duration of CP-induced remission appeared dose-dependent: on day 50 of the administration of 50, 100 and 150 mg/kg body, tumors were detected in 100, 55 and 0% of the animals, respectively. Such means of apoptosis induction as glycocorticoid treatment and ionizing radiation did not cause complete regression.
680. [Chemobiokinetics of sarcolysin and its peptides with glutaminic acid].
作者: T A Mironiuk.;M V Korsakov.;V V Reztsova.;S A Kon'kov.;E A Zhdanova.;V P Krasnov.;V A Filov.
来源: Vopr Onkol. 2000年46卷5期583-7页
A 14C study of chemobiokinetics of sarcolysin and its peptides of glutaminic acid, dosage and routes of administration was conducted in intact rats and those bearing Walker's carcinoma. Similar in shape for peptides, kinetic curves differed from those found for sarcolysin. The rates of absorption and excretion of sarcolysin peptides in intraperitoneal and, particularly, oral administration were lower than those of sarcolysin. Tumor appeared to play a role in a higher rate of peptide excretion. While sarcolysin and its peptides distribution in organs and tissues was generally identical, time of peak radioactive concentration build-up was different. Time needed for accumulation and excretion of peptides from tumor was much longer than from other organs or tissues. Sarcolysin went chiefly to urine while peptides--to faeces.
|